米托蒽醌用于乳腺癌肝转移的II期研究。

Phase II study of mitoxantrone for liver metastases from breast cancer.

作者信息

O'Reilly S M, Coleman R E, Rubens R D

机构信息

ICRF Clinical Oncology Unit, Guy's Hospital, London, U.K.

出版信息

Cancer Chemother Pharmacol. 1989;25(1):73-4. doi: 10.1007/BF00694343.

DOI:10.1007/BF00694343

PMID:2591004

Abstract

Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction. In all, 2 patients received the drug at a dose of 10 mg/m2 on days 1 and 2 of the first course of treatment; 1 patient was given 9 mg/m2 and 17 received 8 mg/m2. Subsequent courses were given at a dose of 10 mg/m2. Three patients (16%) showed a partial response, with time to progression of between 3 and 7 months. Toxicity was considerable, with myelosuppression being the major problem.

摘要

米托蒽醌被给予19例患有乳腺癌肝转移且有肝功能不全生化证据的患者。总共，2例患者在第一个疗程的第1天和第2天接受了10mg/m²剂量的该药物；1例患者接受9mg/m²，17例接受8mg/m²。后续疗程给予10mg/m²的剂量。3例患者（16%）显示部分缓解，疾病进展时间在3至7个月之间。毒性相当大，骨髓抑制是主要问题。